1978 - The Company was incorporated on 21st June, in Uttar Pradesh.
Company manufacture Vinyl Acetate Monomer (VAM). The Company
was promoted by A.B. Bofors (Swedish Multinational),
Wires Ltd., and Mr. M.L. Bhartia.
- The Company entered into a technical collaboration agreement
Noble Chematur Division of A.B. Bofors, Sweden for the supply
know-how and basic engineering for the manufacture of vinyl
1981 - 1,200 No. of equity shares subscribed for by the signatories
the Memorandum of Association. 34,63,800 No. of equity and
38,500 Pref. shares issued through a prospectus during
1982, 19,250 Pref. shares each reserved and allotted to
and PICUP. 6,08,370 No. of equity shares reserved and
to Indian private promoters and their associates, 6,55,430 No.
equity shares reserved and allotted to AB Brothers of Sweden
22,00,000 No. of equity shares offered at par for public
subscription. Pref. shares redeemable during 28.5.1993/96.
1982 - 6,93,000 Rights Equity shares issued at par in prop. 1:5
5,52,043 shares taken up). The remaining 1,40,357 shares
allotted on private placement basis (including 96,800 shares
1983 - Another technical collaboration agreement was signed with
Decorative Products Ltd., U.K., and Reed International
for the manufacture of high pressure emulsions i.e.,
Acetate Emulsions. This project was commissioned in 1985-86.
- During November, the Company promoted `India Glycols Ltd.' to
take up the implementation of a project to manufacture Mono
Ethylene Glyco (MEG) at Kashipur, U.P., in technical
collaboration with Scientific Design Co. Int., U.S.A.
production commenced on 1st January, 1990.
1984 - A technical collaboration agreement was signed with
Spa of Italy for the manufacture of polyvinyl alcohol with an
installed capacity of 2,000 tonnes per annum. The unit was
commissioned in July 1991, with an installed capacity of 650
per annum. During 1991, the capacity was doubled to 1,400
per annum. The Company proposed to enhance the capacity of
2,000 MT per annum by installing additional equipment.
1985 - Vam Leasing Ltd., and Vam Investments Ltd., were incorporated
wholly owned subsidiaries of the Company.
1986 - 10,06,180 No. of equity shares issued at par to financial
institutions on conversion of loans.
1987 - The Company decided to set up a plant to recover carbon
in collaboration with Hydrogas Denmart a.s. of Denmark and
manufacture to dry ice. The plant was commissioned in 1989.
biogas plant was also set up in collaboration with Biotim N.V.
Belgium as a part of energy conservation programme.
- The Company also promoted `Insilco Ltd.' jointly with Degussa
of West Germany for the manufacture of spray dried silica.
project was expected to go on stream by the middle of 1991.
- Applications were also submitted to Government for increasing
production capacity of vinyl acetate monomer from 10,000
to 20,000 tonnes per annum.
- In order to part finance the vinyl acetate monomer project,
during January, the company privately placed with financial
institutions, 15% non-convertible debentures worth Rs 1.00
crores. These debentures are redeemable at a premium of 5%
three equal annual instalments commencing on 27th April,
- The Company privately placed with financial institutions 14%
non-convertible debentures worth Rs 1.50 crores. These
debentures are redeemable in full at a premium of 5% on 29th
1989 - A synthetic wood adhesive Vamicol was launched in January and
liquid and dry carbon-di-oxide (dryice) were launched in
The company installed another new boiler of capacity 25
steam/hour based on the fluidised bed technology to eliminate
- The Company privately placed with financial institutions 14%
non-convertible debentures worth Rs 10 crores. These
are redeemable in full at a premium of 5% on 25th June, 1996.
1990 - The Company commissioned a plant with an installed capacity
500 tonnes per annum for the manufacture of pyridine and
- The Company undertook to expand the production capacities of
vinyl acetate monomer and its intermediaries i.e., acetic
anhydride and acetic acid. The expanded capacities were
commissioned in October 1990.
- The Company privately placed 14% redeemable non-convertible
debentures of Rs 100 each aggregating Rs 5.00 crores. These
debentures are redeemable at a premium of 5% in three equal
annual instalments commencing on 11th September, 1996.
- During the year, another 5,00,000-14% redeemable
debentures of Rs 100 each were privately placed with a
to redeem at a premium of 5% in three equal instalments
commencing on 29th March, 1997.
1992 - Ramganga Fertilizers Ltd. (RFL) was amalgamated with the
effective 1st April, as per BIFR Scheme. As per the scheme
amalgamation 2,56,522 No. of equity shares of Rs 10 each were
issued at par to the shareholders of erstwhile RFL in the
of one equity share of the company for every 10.35 No. of
share of Rs 10 each fully paid-up of the erstwhile RFL.
1995 - A technical collaboration agreement was signed with Kemira
Coatings Ltd., U.K., to manufacture wood finishes a polymer
product. Another agreement was also signed with M/s.
Germany to manufacture construction chemicals in its plant at
- The company proposed to install an additional turbine
with a capacity of 5.5 MW in view of high and frequently
incidence of power failure and fluctuation. The company also
proposed to increase the installed capacity of Pyridine &
Picolines by 4,000 tonnes per annum to meet the increasing
for the products.
- 2,56,522 No. of equity shares issued to the shareholders of
erstwhile RFL on merger of the said company with company.
1996 - The Company proposed to open offices in Singapore to cater to
need of S.E. Asia & China & European markets. With a view to
tackling the power failure and fluctuations, the company
to instal a turbine generator with a capacity of 5.5 MW.
- The company made a capital expenditure of Rs 26.40 crores for
taking up projects such as Pyridene & Picolines, wood
construction chemicals with the intention of saving valuable
foreign Exchange. It was also proposed to modernise its
sulphuric acid plant. With a view to saving energy the
proposed to instal biogas fired boiler.
1997 - The Company faced a sharp decline in sales realisation of
Acid and VAM, due to a combination of the South East Asian
financial debacle and the large capacity build up of Acetic
and VAM in South Korean and Singapore.
- The company has embarked on a substantial capital expenditure
programme to enhance capacities of existing products and also
manufacture new products.
- Vam Organic Chemicals Ltd has registered a 8.97 per cent
in net profit for the year ended March 31, 1997 at Rs.23.07
crores as compared to Rs.21.17 crores in the previous year.
1998 - Vam Organics Chemicals has introduced a specialist adhesive
Vam Bond 2001.
- The dry silica venture, jointly promoted by Vam Organics and
Degussa AG of Germany with a 34 per cent stake each has not
been doing too well.
- The company's performance has been affected due to low
international prices, steady increase in prices of major raw
materials and sluggish growth in the overall market.
- VAM Organic Chemicals Ltd (VOCL) proposes to merge group
companies Anichem India Ltd (AIL) and Enpro Speciality
Ltd (ESCL) with itself.
- A planned shut-down of the fertiliser plant was undertaken for
days in the quarter for revamping. It also increased its
installed capacity from 125 tonnes per day to 175 tonnes per
for sulphuric acid. A captive power plant of 12.45 MW was
commissioned in July this year.
- VAM Organic Chemicals Ltd is exploring the possibility of
entering into areas such as sugar, speciality chemicals and
- The non-convertible debenture programme of Vam Organic
Chemicals Ltd has been downgraded by ICRA to LA- LAA-.
Vam was the largest player in the alcohol-based organic
chemical industry with the largest capacities in the country
for most of its products including acetic acid, acetic
1999 - VAM Organic Chemicals Ltd (VOCL) has proposed to consolidate
improve its existing position in the chemical industry in the
- VOCL has also commissioned the units of Polychem Ltd,
manufacturing alcohol-based chemicals in May.
- The Company's 22,500 tonnes per annum formaldehyde plant has
been commissioned, permitting it to export greater quantities
of picolines and pyridines. It has also installed new
and increased the capacities of existing plants.
-Enters the Bio / chemo informatics arena by setting up Jubilant
-New corporate identity: Jubilant Organosys Ltd. reflecting changed
corporate and business profile
-Acquires the Active Pharmaceutical Ingredients business
-Trading symbol of Jubilant Organosys Limited is changed from
'VAMORGANIC ' to 'JUBILANT'
-Jubliant Securites Pvt. Ltd. & Jubliant Capital Pvt. Ltd has
acquired 4,38,068 (2.99% of total paid up capital) equity shares.
-Mr. H K Khan (Retd. IAS) has been appointed as additional director
with effect from November 05, 2003 on the Board.
-Jubilant Organosys Limited has informed that the Board of Directors
at their meeting held on January 9, 2004 have approved for voluntary
delisting of equity shares of the Company from The Delhi Stock
Exchange Association Limited, The Calcutta Stock Exchange Association
Limited, Kolkata and the Uttar Pradesh Stock Exchange Association
Limited subject to the approval of shareholders by special
-Jubilant Organosys acquires generic pharma Companies in Europe
-Jubilant Organosys signs international contracts worth US$ 60
million in CRAMS for the year 2007
-Acquired pharmaceutical company in USA involved in off patent drug
development and supply, and owns US FDA approved manufacturing
facility for solid dosage forms.
-Acquires full service Clinical Research Organization in USA involved
in providing clinical research services, data management,
biostatistics and contract staffing.
-Acquires Target Research Associates, Inc., renamed Clinsys Inc.; a
US based Clinical Research Organisation (CRO)
-Acquires Trinity Laboratories, Inc. and its wholly owned subsidiary,
Trigen Laboratories, Inc., renamed Jubilant Pharmaceuticals, Inc., a
generic pharmaceutical company in USA having a US FDA approved
formulations manufacturing facility
-Enters Clinsys Clinical Research Ltd. business by setting up wholly
owned subsidiary Jubilant Clinsys Ltd.
-Selected as one of the top 25 companies for Institute of Company
Secretaries of India National Award for Excellence in Corporate
-Finalist in Golden Peacock Award for Excellence in Corporate
-Company has splits its Face value of Shares from Rs 5 to Re 1
-Jubilant Organosys Ltd has acquired 100% equity stake in
Hollister-Stier Laboratories LLC, USA, engaged in high growth
Injectable contract manufacturing and well established and stable
Allergy Immunotherapy businesses.
-Acquires Hollister Stier Laboratories in USA, a contract
manufacturer of Sterile injectable vials and allergenic extracts.
-Acquires DRAXIS Specialty Pharmaceuticals, Inc. Canada, a contract
manufacturer of sterile & non-sterile products and
-Acquires Speciality Molecules Pvt. Ltd. Engaged in the manufacturing
of Fine Chemicals used by Life Science Industry including pharma, agro
& cosmetic industry.
-Jubilant Organosys and Lilly form Drug development joint venture
- Uttar Pradesh-based pharma major Jubilant Organosys Ltd (JOL) has
secured new contracts worth million (Rs.3.7 billion). The
contracts have been signed under Customs Research and Manufacturing
Services (CRAMS). Besides marketing its products in the regulated
markets of the US, Europe and Japan, the company has managed to make
forays into China, said a statement of JOL.
-Jubilant enters into multiple Drug discovery partnerships with
leading pharma and biotech -companies such as AstraZeneca, Orion,
Endo pharmaceuticals & BioLeap and also extends its collaboration
with Lilly for five years.
-Jubilant enters into drug development collaborations with academia,
University of Alabama at Birmingham and Southern Research Institute
(USA) and Duke University (Singapore).
-Jubilant Kalpataru – 120 bed super specialty hospital at Barasat,
Kolkata, India inaugurated by Hon’ble Minister of Finance Shri Pranab
-ET – IMEA 2009 Platinum Award by Frost & Sullivan, in the
Pharmaceutical category for the API facility at Nanjangud
-Best CFO (FMCG, Health and Retail Sector) to Mr. R. Sankaraiah by
Institute of Chartered Accountants of India in January, 2010
- Jubilant Organosys Ltd has appointed Mr. Shardul S. Shroff as
Additional Director of the Company with effect from March 15, 2010.
- Jubilant Organosys Ltd has signed a USD 51 million CRAMS contract
with a leading Life Sciences Company
-The Company has changed from Jubilant Organosys Ltd to JUBILANT LIFE
-Mr. Shardul S. Shroff has been appointed as Additional Director of
-Jubilant Life Sciences Ltd has announced another successful delivery
of an early stage milestone in the Pain therapeutic area.
-Jubilant Org - Jubilant sets up global scale capacities for Symtet -
-JubilantLife - announced today that they have achieved an early
stage milestone in one of their collaborative programs with Chadds
-Jubilant HollisterStier Announces Multi-Million Dollar Award for the
manufacture of Sterile Parenteral Products.
-Jubilant SEZ at Bharuch, inaugurated by Shri Narendra Modi, Hon’ble
Chief Minister of Gujarat.